Optimism is on the rise as the American Cancer Society is reporting that the five-year survival rate for those diagnosed with pancreatic has increased to 12%—representing an increase of 1% over

Astellas Pharma Inc. today announced positive topline results from the Phase 3 China ARCHES study of XTANDI® plus androgen deprivation therapy in men with metastatic hormone-sensitive

On March 7th, 2023, Suzhou Porton Advanced Solutions Ltd. and Bennu Biotherapeutics announced a strategic partnership to advance cell and gene therapy R&D pipelines.

Sumitovant Biopharma Ltd.and Myovant Sciences Ltd. announced today that Sumitovant has successfully completed its acquisition of Myovant originally announced October 23, 2022.

Endo International plc announced today that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping the first generic version of Allergan's Pylera® 140 mg, 125 mg and 125

Shuttle Pharmaceuticals Holdings, Inc.a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with

Microbion Corporation today announced that a Phase 2, randomized, controlled study has been initiated to assess the safety and efficacy of topical pravibismane for the treatment of subjects

InvoX Pharma Limited a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited with an advancing pipeline of innovative products, today announces that it has successfully

IBSA Pharma announced today that it has entered into an agreement with Mark Cuban Cost Plus Drug Company, PBC to offer Tirosint® oral capsules at a low cash price via the Cost Plus Drugs

On the eve of International Women’s Day, BioSyent Inc. celebrates the Canadian launch of FeraMAX® Pd Maintenance 45 by its subsidiary, BioSyent Pharma Inc. FeraMAX® Pd